|| Checking for direct PDF access through Ovid
The technique of laparoscopic ventral rectopexy using biologic mesh to manage pelvic floor disorders is relatively new.Data from all consecutive patients undergoing laparoscopic ventral rectopexy wereprospectively entered in a database. Outcome parameters were Wexner constipation and incontinence scores, early and late complications and recurrence. Results were compared using Wilcoxon signed rank tests (two-tailed p-test).Fifty-eight patients (median age 62, range 31-89) underwent laparoscopic ventral rectopexy with a PermacolTM (Covidien, North Haven, CT, USA) mesh between May 2008 and May 2010 (median follow-up 6 months, range 1-24). Theprimary indications for surgery were full-thickness rectalprolapse (n = 24), rectocele with obstructive defaecation symptoms (n = 21), vaginal vaultprolapse (n = 12) and faecal incontinence (n = 1). Improvements in Wexner constipation and faecal incontinence scores were significant at 6 months (n = 38) and 1 year (n = 23) (P < 0.05). At 6 months and 1 year symptoms were rated as much better or better by 92% and 95% of patients respectively. Nobody stated a worsening of symptoms. There was one conversion to an openprocedure. Early complications occurred in five patients (9%) and late complications in two patients (3%). There was no mortality. Recurrence of symptoms occurred in two patients (3%).Laparoscopic ventral rectopexy using biologic mesh is a safe and effective treatment for pelvic organprolapse, including the underlying functional disorder.